No, I do not recommend initiating PRN hydroxyzine for anxiety in adults
Hydroxyzine is not included in current evidence-based guidelines for anxiety treatment and should not be used as a first-line or routine intervention. The most recent and authoritative guideline for anxiety disorders (2023) explicitly recommends SSRIs (such as fluvoxamine, paroxetine, or escitalopram) or the SNRI venlafaxine as first-line pharmacotherapy, with cognitive behavioral therapy as the preferred psychotherapy 1.
Why Hydroxyzine Is Not Recommended
Guideline Evidence
The 2023 Japanese Society of Anxiety and Related Disorders/Japanese Society of Neuropsychopharmacology guidelines make no mention of hydroxyzine in their treatment algorithm for social anxiety disorder or generalized anxiety 1. This is a critical omission—if hydroxyzine were considered appropriate therapy, it would appear in these comprehensive, evidence-based recommendations.
The guidelines clearly state that for adults ≥18 years with anxiety disorders:
- First-line pharmacotherapy: SSRIs (weak recommendation, low certainty evidence) 1
- Alternative pharmacotherapy: Venlafaxine SNRI (weak recommendation, low certainty evidence) 1
- First-line psychotherapy: Individual CBT using Clark/Wells or Heimberg models 1
Research Evidence Limitations
While older studies (1994-2002) showed hydroxyzine had some efficacy over placebo for GAD 2, 3, 4, a 2010 Cochrane systematic review concluded: "it is not possible to recommend hydroxyzine as a reliable first-line treatment in GAD" due to high risk of bias in included studies, small sample sizes, and limited evidence 5.
More recent evidence (2021) found that hydroxyzine added to morphine for acute pain did not reduce anxiety in the prehospital setting 6, suggesting limited real-world effectiveness even in acute situations.
FDA Labeling Concerns
The FDA label explicitly states: "The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies" 7. This is a significant limitation for a chronic condition like anxiety disorders, which typically require sustained treatment.
What to Do Instead
For Generalized Anxiety or Social Anxiety:
- Start with an SSRI (escitalopram, paroxetine, or sertraline) as daily scheduled medication 1, 8
- Refer for CBT if available, particularly individual therapy with a trained therapist 1
- Consider venlafaxine if SSRIs are ineffective or not tolerated 1
For Acute/Intermittent Anxiety:
- Avoid PRN benzodiazepines due to dependence risk with long-term use 8
- Teach evidence-based behavioral strategies (breathing exercises, grounding techniques) rather than relying on PRN medications
- If PRN medication is absolutely necessary while awaiting SSRI effect, use the lowest effective dose for the shortest duration, but recognize this is not guideline-supported
Common Pitfalls to Avoid
Pitfall #1: Using hydroxyzine because "it's safer than benzodiazepines"—while it may have less dependence potential, it's still not evidence-based first-line therapy and causes sedation 5, 2.
Pitfall #2: Prescribing PRN medications without addressing the underlying anxiety disorder with scheduled treatment—anxiety disorders require consistent daily therapy, not as-needed approaches 1, 7.
Pitfall #3: Assuming older medications are equivalent to newer evidence-based treatments—hydroxyzine studies are from the 1990s-2000s and have not been incorporated into modern treatment algorithms 5.
The FDA label does indicate hydroxyzine is approved for "symptomatic relief of anxiety and tension associated with psychoneurosis" at doses of 50-100 mg four times daily 7, but approval does not equal optimal or guideline-concordant care. Modern evidence prioritizes SSRIs and CBT for better long-term outcomes in morbidity, mortality, and quality of life 1, 8.